Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

Understanding the Dietary Adjustments Following GLP-1 Agonist Treatment: The GLaD Feasibility Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07001553

Acronym

GLaD

Enrollment

Registered

2025-06-03

Start date

2025-05-28

Completion date

2026-01-07

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Type 2 Diabetes Mellitus (T2DM)

Keywords

dietary behaviours, psychosocial health

Brief summary

An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health.

Detailed description

Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will be recruited to participate over the initial 3 months of their treatment. Assessments will occur remotely (online) at baseline, 2 weeks, 1 month and 3 months. Optional body composition assessments will be provided at baseline and 3 months for those based in Melbourne, Australia.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged 18+ years old * Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months * The primary reason for commencing the medication will be for diabetes or weight management * Willing to participate in dietary recall and questionnaires

Exclusion criteria

* Aged under 18 years, * used a GLP-1 agonist medication in the previous 6 months, * unwilling or unable to provide dietary recalls * non-English speaking.

Design outcomes

Primary

Measure	Time frame	Description
Feasibility of recruitment	4 months	The rate of recruitment and the retention rate of participants completing the dietary assessment measures.

Secondary

Measure	Time frame	Description
Energy intake	baseline, 2 weeks, 1 month, 3 months	Assessed using Intake24 records for at least 2 days per timepoint
Medication symptomology	baseline, 1 month, 3 months	Incidence of self-reported side effects
Medication use	baseline, 1 month, 3 months	Dosage

Countries

Australia

Contacts

PRINCIPAL_INVESTIGATOREvelyn B Parr, PhD

Australian Catholic University

Outcome results